Skip to content

Clinical study of Tonghua Liyan recipe in the treatment of laryngopharyngeal reflux with Qi stagnation and phlegm obstruction: A randomized, double-blind, placebo-controlled trial

Clinical study of Tonghua Liyan recipe in the treatment of laryngopharyngeal reflux with Qi stagnation and phlegm obstruction

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046614
Enrollment
Unknown
Registered
2021-05-23
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease

Interventions

Sponsors

Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of laryngopharyngeal reflux (electronic gastroscopy and electronic laryngoscopy within 6 months before enrollment); 2. TCM syndrome differentiation of patients belongs to Qi stagnation and phlegm obstruction; 3. Patients who had not taken acid suppressants or gastrointestinal motility drugs 2 weeks before enrollment; 4. Aged 18 to 70 years, regardless of gender; 5. Patients who understand and agree to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients have one of the following diseases: peptic ulcer, history of gastroesophageal and duodenal surgery, Zollinger-Ellison syndrome, pyloric obstruction, primary esophageal motility disorders (e.g. cardia achalasia, scleroderma, primary esophageal spasm), drug esophagitis, fungal esophagitis, gastrointestinal malignancy; 2. Patients with serious primary diseases of heart, brain, liver, lung, kidney, blood and endocrine system, which have not been effectively controlled, and patients with severe mental illness; 3. Patients who cannot take medication during pregnancy preparation, pregnancy or lactation, and patients who are allergic to the medication used in this study, and patients who cannot cooperate in taking medication and completing related records due to various circumstances; 4. Patients who have participated in or are participating in other clinical trials 2 weeks before enrollment.

Design outcomes

Primary

MeasureTime frame
Reflux Symptom Index;Clinical Symptom Score;Reflux Finding Score;Electronic Gastroscopy;

Secondary

MeasureTime frame
Salivary Pepsin;Gastroesophageal Reflux Disease Questionnaire;

Countries

China

Contacts

Public ContactZhou Bingduo

Yueyang Integrated Traditional Chinese and Western Medicine Hospital affiliated to Shanghai University of Traditional Chinese Medicine

bingduozhou@163.com+86 21 65161782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026